

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/535,047	01/05/2006	Sara Brett	PG5029	9414
20462 7590 01/07/2008 SMITHKLINE BEECHAM CORPORATION CORPORATE INTELLECTUAL PROPERTY-US, UW2220			EXAMINER ·	
			LUCAS, ZACHARIAH	
P. O. BOX 15 KING OF PRI	BOX 1539 GOF PRUSSIA, PA 19406-0939		ART UNIT	PAPER NUMBER
Idirio of The	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		1648	
			NOTIFICATION DATE	DELIVERY MODE
			01/07/2008	ELECTRONIC

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Notice of the Office communication was sent electronically on above-indicated "Notification Date" to the following e-mail address(es):

US_cipkop@gsk.com

	Application No.	Applicant(s)				
	10/535,047	BRETT ET AL.				
Office Action Summary	Examiner	Art Unit				
	Zachariah Lucas	1648				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address Period for Reply						
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DATE of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication. If NO period for reply is specified above, the maximum statutory period value of the provision of the	ATE OF THIS COMMUNIC 36(a). In no event, however, may a re vill apply and will expire SIX (6) MON , cause the application to become AB	CATION. eply be timely filed THS from the mailing date of this communication. ANDONED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on <u>05 January 2006</u> .						
2a) This action is FINAL. 2b) This	This action is FINAL. 2b) This action is non-final.					
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is						
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4) Claim(s) 1-16 and 19-22 is/are pending in the application.						
4a) Of the above claim(s) is/are withdrawn from consideration.						
5) Claim(s) is/are allowed.						
6) Claim(s) is/are rejected.						
7) Claim(s) is/are objected to.						
8) Claim(s) <u>1-16 and 19-22</u> are subject to restrict	ion and/or election require	ment.				
Application Papers						
9) The specification is objected to by the Examine	er.					
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).						
11)☐ The oath or declaration is objected to by the Ex	caminer. Note the attached	d Office Action or form PTO-152.				
Priority under 35 U.S.C. § 119						
12)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). a)⊠ All b)□ Some * c)□ None of:						
1. Certified copies of the priority documents have been received.						
2. Certified copies of the priority documents have been received in Application No						
3. Copies of the certified copies of the priority documents have been received in this National Stage						
application from the International Bureau	,					
* See the attached detailed Office action for a list of the certified copies not received.						
Attachment(s)						
 Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948) 		Summary (PTO-413) s)/Mail Date				
3) Information Disclosure Statement(s) (PTO/SB/08)	5) 🔲 Notice of Ir	nformal Patent Application				
Paper No(s)/Mail Date 6) Uther:						

10/535,047 Art Unit: 1648

DETAILED ACTION

Election/Restrictions

1. This application contains claims directed to more than one species of the generic invention. These species are deemed to lack unity of invention because they are not so linked as to form a single general inventive concept under PCT Rule 13.1.

The species are as follows:

Applicant is required to elect an embodiment of the claimed invention wherein the polynucleotide encodes one of

- (a) HCV core protein (claims 1-6, 9, 19-22)
- (b) HCV NS3 protein (claims 1, 6, 9, 12, 14, 15, 19-22)
- (c) HCV NS4B protein (claims 1, 6, 9, 12, 16, 19-22),
- (d) HCV NS5B protein (claims 1, 6, 9, 12, 13, 19-22), or
- (e) a combination comprising the NS4B and NS5B proteins (claims 1, 6, 7, 9, 12, 13, 16, 19-22), or
- (f) a combination thereof comprising the core and NS3 protein (claim1, 6-10, 12, 14, 15, 19-22), or
 - (g) a combination comprising the core and NS5B protein (claims 1, 9-13, 19-22_.

Further, if either of species (b) or (f) is elected above, Applicant is further required to elect an embodiment wherein the NS3 sequence is mutated in (i) the catalytic triad (claim 14),

10/535,047

Art Unit: 1648

(ii) in motif I (claim 15), (iii) in motif II (claim 15), (iv) in motif III (claim 15), or (v) in motif IV (claim 15).

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

- 2. The claims are deemed to correspond to the species as listed above.
- No claim(s) are generic.
- 3. The species listed above do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, the species lack the same or corresponding special technical features for the following reasons: the common technical feature of the claimed invention is the presence of a polynucleotide encoding an HCV Core, NS3, NS4b, and/or NS5b protein. Such a polynucleotide is known in the prior art. See e.g., WO 01/38360 (of record in the May 13, 2005 IDS), claims 20-24 and 42. Unity of invention is therefore lacking.

Conclusion

4. Applicant is advised that the reply to this requirement to be complete must include (i) an election of a species or invention to be examined even though the requirement be traversed (37 CFR 1.143) and (ii) identification of the claims encompassing the elected invention.

10/535,047 Art Unit: 1648

The election of an invention or species may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly and specifically point out supposed errors in the restriction requirement, the election shall be treated

as an election without traverse.

Should applicant traverse on the ground that the inventions or species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the inventions or species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence, or admission may be used in a rejection under 35 U.S.C.103 (a) of the other invention.

- 5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).
- 6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Zachariah Lucas whose telephone number is 571-272-0905. The examiner can normally be reached on Monday-Friday, 8 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Bruce Campell can be reached on 571-272-0974. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

10/535,047

Art Unit: 1648

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Z. Lucas/ Patent Examiner, AU 1648